

Betreuung von Patienten mit einem Nierenersatzverfahren – Teil 2

Kardiovaskuläre, infektiologische, diabetologische, dermatologische, neurologische, psychiatrische, nutritive und pharmakologische Aspekte

Prise en charge des patients sous substitution rénale – 2ème partie

Aspects cardiovasculaires, infectiologiques, diabétologiques, dermatologiques, neurologiques, psychiatriques, nutritionnels et pharmacologiques

Literatur / Références

1. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease:Improving Global Outcomes (KDIGO). *Kidney Int* 2011;80:572–586
2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 2004;351:1285–1295
3. Fox CS, Muntner P, Chen AY, Alexander RP, Roe MT, Cannon CP et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010;121:357–365
4. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. *J Am Soc Nephrol* 2012;23:2042–2049
5. Krüger T, Brandenburg V, Schlieper G, Marx N, Floege J. Sailing between Scylla and Charybdis: oral long-term anti-coagulation in dialysis patients. *Nephrol Dial Transplant* 2013;28:534–541
6. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens* 2013;31:1925–1938
7. Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. *Semin Dial* 2010;23:290–297
8. Kramann R, Floege J, Ketteler M, Marx N, Brandenburg VM. Medical options to fight mortality in end-stage renal disease: a review of the literature. *Nephrol Dial Transplant* 2012;27:4298–4307
9. KDIGO 2013 Clinical Practice Guideline for lipid management in chronic kidney disease. *Kidney Int Supplements* 2013;3:271–279
10. Wessely M, Rau S, Lange P, Kehl K, Renz V, Schönermarck U et al. Chronic kidney disease is not associated with a higher risk for mortality or acute kidney injury in transcatheter aortic valve implantation. *Nephrol Dial Transplant* 2012;27:3502–3508
11. Perl J, Unruh ML, Chan CT. Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis?' *Kidney Int* 2006;70:1687–1693
12. Dalrymple LS, Johansen KL, Chertow GM, Cheng SC, Grimes B, Gold EB et al. Infection-related hospitalizations in older patients with ESRD. *Am J Kidney Dis* 2010;56:522–530
13. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. *J Am Soc Nephrol* 2003;14:1863–1870
14. Li PK, Chow KM. Infectious complications in dialysis—epidemiology and outcomes. *Nat Rev Nephrol* 2011;8:77–88
15. Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. *Neph Dial Transplant* 2011;26:2934–2939
16. KDIGO 2012 Clinical Practice Guideline for the Evaluation and management of chronic kidney disease. *Kidney Int Supplements* 2013;3:91–111
17. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2012;55:1577–1596
18. Kidney Disease:Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. *Am J Transplant* 2009;9(Suppl 3):1–157
19. Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. *Clin Dermatol* 2008;26:255–264
20. Brandenburg VM, Kramann R, Specht P, Ketteler M. Calciphylaxis in CKD and beyond. *Nephrol Dial Transplant* 2012;27:1314–1318

21. Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. *Kidney Int* 2012;81:247–255
22. Murray AM, Tupper DE, Knopmann DS, Gilbertson DT, Pederson SL, Li S et al. Cognitive impairment in hemodialysis patients is common. *Neurology* 2006;67:216–223
23. Hermann DM, Grotz W. Kognitive Beeinträchtigung bei chronischer Nierenerkrankung. *Nephrologe* 2013;8:323–326
24. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. *Nat Rev Neurol* 2009;5:542–551
25. Heng AE, Cano NJM. Nutritional problems in adult patients with stage 5 chronic kidney disease on dialysis (both haemodialysis and peritoneal dialysis). *NDTplus* 2010;3:109–117
26. National Kidney Foundation (NKF) K/DOQI. Clinical practice guidelines for nutrition in chronic kidney failure. *Am J Kidney Dis* 2001;35:S1–S140
27. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. *Expert Opin Drug Metab Toxicol* 2008;4:1065–1074